COMPASS Pathways Plc - American Depository Shares (CMPS)

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid investor disappointment

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

CMPS earnings call for the period ending December 31, 2024.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.